P1101: PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REVERSIBLE) BTK INHIBITOR IN PREVIOUSLY TREATED MANTLE CELL LYMPHOMA: UPDATED RESULTS FROM THE PHASE 1/2 BRUIN STUDY

• T. A. Eyre,
• M. L. Wang,
• N. N. Shah,
• A. J. Alencar,
• J. N. Gerson,
• M. R. Patel,
• B. Fakhri,
• E. Vandenberghe,
• W. Jurczak,
• X. N. Tan,
• K. L. Lewis,
• T. Fenske,
• Y. Wang,
• C. C. Coombs,
• I. Flinn,
• D. Lewis,
• S. Le Gouill,
• M. Gandhi,
• C. Chay,
• M. L. Palomba,
• J. A. Woyach,
• J. M. Pagel,
• N. Lamanna,
• J. P. Sharman,
• D. J. Andorsky,
• J. B. Cohen,
• M. A. Barve,
• P. Ghia,
• M. Yin,
• P. L. Zinzani,
• C. Ujjani,
• Y. Koh,
• K. Izutsu,
• E. Lech-Maranda,
• J. Kherani,
• C. Tam,
• S. Sundaram,
• B. Nair,
• D. E. Tsai,
• M. Balbas,
• A. R. Mato,
• C. Y. Cheah

Affiliations

T. A. Eyre

1 Oxford University Hospitals NHS Foundation Trust, Churchill Cancer Center, Oxford, United Kingdom

M. L. Wang

2 MD Anderson Cancer Center, Houston

N. N. Shah

3 Medical College of Wisconsin, Milwaukee

A. J. Alencar

4 Sylvester Comprehensive Cancer Center, Miami

J. N. Gerson

5 University of Pennsylvania, Philadelphia

M. R. Patel

6 Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota

B. Fakhri

7 University of California San Francisco, San Francisco, United States of America

E. Vandenberghe

8 Hope Directorate St. James Hospital, Dublin, Ireland

W. Jurczak

9 Maria Sklodowska-Curie National Research Institute of Oncology, Krakow, Poland

X. N. Tan

10 Linear Clinical Research and Sir Charles Gairdner Hospital, Perth, Australia

K. L. Lewis

10 Linear Clinical Research and Sir Charles Gairdner Hospital, Perth, Australia

T. Fenske

3 Medical College of Wisconsin, Milwaukee

Y. Wang

11 Division of Hematology, Mayo Clinic, Rochester

C. C. Coombs

12 University of North Carolina at Chapel Hill, Chapel Hill

I. Flinn

13 Sarah Cannon Research Institute, Nashville, United States of America

D. Lewis

14 University Hospitals Plymouth NHS, Plymouth, United Kingdom

S. Le Gouill

15 Service d’hématologie clinique du CHU de Nantes, INSERM CRCINA Nantes-Angers, NeXT Université de Nantes, Nantes, France

M. Gandhi

16 Virginia Cancer Specialists, Fairfax

C. Chay

17 Messino Cancer Centers, Asheville

M. L. Palomba

18 Memorial Sloan Kettering Cancer Center, New York

J. A. Woyach

19 The Ohio State University Comprehensive Cancer Center, Columbus

J. M. Pagel

20 Loxo Oncology at Lilly, Stamford

N. Lamanna

21 Herbert Irving Comprehensive Cancer Center, Columbia University, New York

J. P. Sharman

22 Willamette Valley Cancer Institute and Research Center, US Oncology Research

D. J. Andorsky

23 Rocky Mountain Cancer Centers, US Oncology Research, Eugene

J. B. Cohen

24 Winship Cancer Institute, Emory University, Atlanta

M. A. Barve

25 Mary Crowley Cancer Research, Dallas, United States of America

P. Ghia

26 Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milan, Italy

M. Yin

20 Loxo Oncology at Lilly, Stamford

P. L. Zinzani

28 Institute of Hematology “Seràgnoli” University of Bologna, Bologna, Italy

C. Ujjani

29 Fred Hutchinson Cancer Research Center, Seattle, United States of America

Y. Koh

30 Internal Medicine, Seoul National University Hospital, Seoul, South Korea

K. Izutsu

31 National Cancer Center Hospital, Tokyo, Japan

E. Lech-Maranda

32 Institute of Hematology and Transfusion Medicine, Warsaw, Poland

J. Kherani

20 Loxo Oncology at Lilly, Stamford

C. Tam

33 Peter MacCallum Cancer Center, Royal Melbourne Hospital, and University of Melbourne, Melbourne, Australia

S. Sundaram

34 Hematology and Medical Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, United States of America

B. Nair

20 Loxo Oncology at Lilly, Stamford

D. E. Tsai

20 Loxo Oncology at Lilly, Stamford

M. Balbas

20 Loxo Oncology at Lilly, Stamford

A. R. Mato

18 Memorial Sloan Kettering Cancer Center, New York

C. Y. Cheah

10 Linear Clinical Research and Sir Charles Gairdner Hospital, Perth, Australia